Kidney-produced erythropoietin (EPO) desensitizes tumors to the effects of antiangiogenic drugs, improving the understanding of the mechanisms underlying resistance to these agents and potentially, how to improve their therapeutic efficacy.
Kidney-produced erythropoietin (EPO) desensitizes tumors to the effects of antiangiogenic drugs, improving the understanding of the mechanisms underlying resistance to these agents and potentially, how to improve their therapeutic efficacy.
A new Japanese study has shown that most mutations in induced pluripotent stem (iPS) cells arising during their generation occur in non-transcriptional areas of the genome. The authors argue this means such mutations are unlikely to cause malignancy.
The discovery of distinct microbial communities along the female reproductive tract from the vagina to fallopian tube, using genetic amplification (amplicon) technology, challenge the traditional view of human fetal development taking place in a sterile environment, a new Chinese study has found.
The discovery of distinct microbial communities along the female reproductive tract from the vagina to fallopian tube, using genetic amplification (amplicon) technology, challenge the traditional view of human fetal development taking place in a sterile environment, a new Chinese study has found.
Erythropoietin (EPO)-producing cells derived from human induced pluripotent stem (iPS) cells have been shown for the first time to be capable of successfully treating renal anemia in mice, Japanese researchers reported in the Sept. 27, 2017, edition of Science Translational Medicine.
A new Indian study showing that selectively targeting signal-regulating proteins with intrabodies provides a novel means of fine-tuning G protein-coupled receptor (GPCR) functions has important implications for new drug development.
A new Indian study showing that selectively targeting signal-regulating proteins with intrabodies provides a novel means of fine-tuning G protein-coupled receptor (GPCR) functions has important implications for new drug development.
Erythropoietin (EPO)-producing cells derived from human induced pluripotent stem (iPS) cells have been shown for the first time to be capable of successfully treating renal anemia in mice, Japanese researchers reported in the Sept. 27, 2017, edition of Science Translational Medicine.
Researchers at National Taiwan University (NTU) in Taipei have developed a new stem cell-based treatment modality, which may prevent damage to the growth phase of hair follicles due to cancer therapies. The findings may lead to the first effective treatment for preventing hair loss in cancer patients.
